Noxopharm (ASX:NOX) has appointed Dr Olivier Laczka as its new Chief Executive Officer with immediate effect, marking a leadership transition as the clinical-stage company positions itself to capitalise on emerging opportunities in its pipeline.
Dr Laczka succeeds Dr Gisela Mautner and steps into the role after serving as Chief Scientific Officer for inflammation, where he played a central role in shaping the company’s scientific and strategic direction.
A longstanding member of the leadership team, Dr Laczka has been instrumental in developing the company’s Sofra platform, a technology with applications across inflammatory and autoimmune diseases, RNA therapeutics, and vaccines. The company said his appointment will ensure continuity as Noxopharm builds on recent momentum, including progress from the HERACLES clinical trial and the publication of research in a leading scientific journal.
Chairman Fred Bart highlighted Dr Laczka’s contribution to the company’s evolution and expressed confidence in his ability to guide its future direction. “Dr Laczka has made a very significant contribution to the development of the Sofra program and is the ideal person to steer the next phase of our growth. He has led our scientific team with genuine vision and energy while forming deep collaborative relationships with our external partners, and we have real confidence in his ability to deliver value for our shareholders.”
Dr Laczka said he was honoured to take on the role and emphasised a focus on disciplined growth and strategic decision-making. “I am honoured to have been entrusted by the Board in this new role, and will take responsibility for building the company in our shareholders’ best interests. We have a real opportunity to grow by seizing the opportunities that are opening up for us, and not hesitating to make the right decisions that will take us forward.”